Pancreatic Insufficiency Drug Makers Given NDA Approval Deadline Of 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is not removing unapproved products from the market because they are medically necessary. However, manufacturers must obtain approval of exocrine pancreatic insufficiency drugs within four years.